Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Interferon beta-1a + doxycycline
- Development stage
- Preclinical
- Lead developer
- Biogen
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intramuscular, Subcutaneous, Oral, Intravenous
01
Overview
Interferon beta-1a + doxycycline is a combination therapy investigated primarily for the treatment of multiple sclerosis (MS), particularly relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS). Interferon beta-1a is an immunomodulator that binds to type I interferon receptors, activating the JAK/STAT pathway and upregulating antiviral proteins, reducing inflammation and preventing nerve damage. Doxycycline is a tetracycline antibiotic with additional properties as an inhibitor of matrix metalloproteinases, which may help protect neurons and oligodendrocytes. Clinical studies suggest this combination can reduce relapse rates and improve disability scores in MS patients, though effects on MRI lesion activity are less clear[1][2][3][5]. The combination has been found to be generally safe and well tolerated in small clinical trials.
- Brand names
- Vibramycin
- Other names
- IFN-beta 1a + doxycycline
02
Targets
MMP12 (Macrophage Metalloelastase)NeuraminidaseIFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on Interferon beta-1a + doxycycline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Interferon beta-1a + doxycycline.